Morgan Stanley’s 10 Best Fresh Money Stocks To Buy

From the healthcare sector, Morgan Stanley analysts chose Iqvia Holdings Inc (NYSE:IQV), mainly due to the company’s therapeutics expertise and scale, with Iqvia Holdings having a large number of top biotech and pharmaceutical companies among its clients.

So far, Iqvia Holdings Inc (NYSE:IQV) has failed to live up to Morgan Stanley’s expectations. The stock has ended Friday’s session at $99.02 per share, down 0.7% since March 23, when Michael Wilson appeared on CNBC. Iqvia Holdings Inc (NYSE:IQV) has recently published its first quarter results, topping Wall Street’s estimates. Revenues came in at $2.56 billion, above the analysts’ consensus of $2.44 billion, while earnings per share rose 20% year-over-year to $1.34, also surpassing analysts’ projections. Having had a solid first quarter, the company’s management decided to adjust its full-year guidance and raised revenue estimates by $50 million. However, the management said it does not expect higher revenue to translate into higher profits, which put investors off.